PureTech Health (PureTech Health) Cash-to-Debt : 12.91 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is PureTech Health Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PureTech Health's cash to debt ratio for the quarter that ended in Dec. 2023 was 12.91.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PureTech Health could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for PureTech Health's Cash-to-Debt or its related term are showing as below:

PRTC' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.13 Med: 11 Max: 63.14
Current: 12.91

During the past 12 years, PureTech Health's highest Cash to Debt Ratio was 63.14. The lowest was 4.13. And the median was 11.00.

PRTC's Cash-to-Debt is ranked better than
59.46% of 1527 companies
in the Biotechnology industry
Industry Median: 6.24 vs PRTC: 12.91

PureTech Health Cash-to-Debt Historical Data

The historical data trend for PureTech Health's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

PureTech Health Cash-to-Debt Chart

PureTech Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

4.13

5.27

8.83

7.47

12.91

PureTech Health Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															8.83	7.65	7.47	13.77	12.91

Competitive Comparison of PureTech Health's Cash-to-Debt

For the Biotechnology subindustry, PureTech Health's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PureTech Health's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where PureTech Health's Cash-to-Debt falls into.

PureTech Health Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

PureTech Health's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	327.143	/	(7.093	+	18.25)
	=	12.91

PureTech Health's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	327.143	/	(7.093	+	18.25)
	=	12.91

PureTech Health (NAS:PRTC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

PureTech Health Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of PureTech Health's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health (PureTech Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (NAS:PRTC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PTCHF:USA PRTCl:UK PRTC:UK PRTCL:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.